AAAAAA

   
Results: 1-18 |
Results: 18
In vitro production of dendritic cells from human blood monocytes for therapeutic use
Authors: Garderet, L Cao, H Salamero, J Verge, V Tisserand, E Scholl, S Gorin, NC Lopez, M
Citation: L. Garderet et al., In vitro production of dendritic cells from human blood monocytes for therapeutic use, J HEMATH ST, 10(4), 2001, pp. 553-567
Proteomics-based identification of RS/DJ-1 as a novel circulating tumor antigen in breast cancer
Authors: Le Naour, F Misek, DE Krause, MC Deneux, L Giordano, TJ Scholl, S Hanash, SM
Citation: F. Le Naour et al., Proteomics-based identification of RS/DJ-1 as a novel circulating tumor antigen in breast cancer, CLIN CANC R, 7(11), 2001, pp. 3328-3335
Response to chemotherapy is a major parameter-influencing long-term survival of metastatic breast cancer patients
Authors: Pierga, JY Robain, M Jouve, M Asselain, B Dieras, V Beuzeboc, P Palangie, T Dorval, T Extra, JM Scholl, S Pouillart, P
Citation: Jy. Pierga et al., Response to chemotherapy is a major parameter-influencing long-term survival of metastatic breast cancer patients, ANN ONCOL, 12(2), 2001, pp. 231-237
Targeting HER2 in other tumor types
Authors: Scholl, S Beuzeboc, P Pouillart, P
Citation: S. Scholl et al., Targeting HER2 in other tumor types, ANN ONCOL, 12, 2001, pp. 81-87
Hyperinsulinism in syndromal disorders
Authors: Meissner, T Rabl, W Mohnike, K Scholl, S Santer, R Mayatepek, E
Citation: T. Meissner et al., Hyperinsulinism in syndromal disorders, ACT PAEDIAT, 90(8), 2001, pp. 856-859
Neonatal screening for medium chain acyl-CoA deficiency: high incidence inLower Saxony (northern Germany)
Authors: Sander, S Janzen, N Janetzky, B Scholl, S Steuerwald, U Schafer, J Sander, J
Citation: S. Sander et al., Neonatal screening for medium chain acyl-CoA deficiency: high incidence inLower Saxony (northern Germany), EUR J PED, 160(5), 2001, pp. 318-319
In vitro generation of dendritic cells from human blood monocytes in experimental conditions compatible for in vivo cell therapy
Authors: Cao, H Verge, V Baron, C Martinache, C Leon, A Scholl, S Gorin, NC Salamero, J Assari, S Bernard, J Lopez, M
Citation: H. Cao et al., In vitro generation of dendritic cells from human blood monocytes in experimental conditions compatible for in vivo cell therapy, J HEMATH ST, 9(2), 2000, pp. 183-194
Predictive factors of response to first-line chemotherapy in 1426 women with metastatic breast cancer
Authors: Robain, M Pierga, JY Jouve, M Asselain, B Dieras, V Beuzeboc, P Palangie, T Dorval, T Extra, JM Scholl, S Pouillart, P
Citation: M. Robain et al., Predictive factors of response to first-line chemotherapy in 1426 women with metastatic breast cancer, EUR J CANC, 36(18), 2000, pp. 2301-2312
Credit local agencies
Authors: Scholl, S
Citation: S. Scholl, Credit local agencies, CIVIL ENG, 70(10), 2000, pp. 6-6
Budgeting novel anti-cancer drugs: with which resources?
Authors: Livartowski, A Beuzeboc, P Le Vu, B Courbard, M Pierga, JY Extra, JM Scholl, S Pouillart, P
Citation: A. Livartowski et al., Budgeting novel anti-cancer drugs: with which resources?, B CANCER, 87(10), 2000, pp. 745-754
Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer
Authors: Pierga, JY Mouret, E Dieras, V Laurence, V Beuzeboc, P Dorval, T Palangie, T Jouve, M Vincent-Salomon, A Scholl, S Extra, JM Asselain, B Pouillart, P
Citation: Jy. Pierga et al., Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer, BR J CANC, 83(11), 2000, pp. 1480-1487
The influence of structure and lipophilicity of hydantoin derivatives on anticonvulsant activity
Authors: Scholl, S Koch, A Henning, D Kempter, G Kleinpeter, E
Citation: S. Scholl et al., The influence of structure and lipophilicity of hydantoin derivatives on anticonvulsant activity, STRUCT CHEM, 10(5), 1999, pp. 355-366
Neoadjuvant chemotherapy in young breast cancer patients: Correlation between response and relapse?
Authors: Braud, AC Asselain, B Scholl, S De la Rochefordiere, A Palangie, T Dieras, V Pierga, JY Dorval, T Jouve, M Beuzeboc, P Pouillart, P
Citation: Ac. Braud et al., Neoadjuvant chemotherapy in young breast cancer patients: Correlation between response and relapse?, EUR J CANC, 35(3), 1999, pp. 392-397
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
Authors: Cobleigh, MA Vogel, CL Tripathy, D Robert, NJ Scholl, S Fehrenbacher, L Wolter, JM Paton, V Shak, S Lieberman, G Slamon, DJ
Citation: Ma. Cobleigh et al., Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease, J CL ONCOL, 17(9), 1999, pp. 2639-2648
Neonatal scurvy
Authors: Dammeier, BG Warmann, S Scholl, S Gluer, S
Citation: Bg. Dammeier et al., Neonatal scurvy, MONATS KIND, 147(6), 1999, pp. 570-572
Thermal integration, an element in design of chemical engineering processes
Authors: Aust, E Scholl, S
Citation: E. Aust et S. Scholl, Thermal integration, an element in design of chemical engineering processes, CHEM-ING-T, 71(7), 1999, pp. 674-679
CAPE in practice - Opportunities and limits from the user's point of view
Authors: Lohe, B Bessling, B Schoenmakers, H Scholl, S Staatz, H
Citation: B. Lohe et al., CAPE in practice - Opportunities and limits from the user's point of view, CHEM-ING-T, 71(4), 1999, pp. 323-327
Herceptin, a monoclonal humanized antibody anti-HER2: a major therapeutic progress in breast cancers overexpressing this oncogene
Authors: Beuzeboc, P Scholl, S Garau, XS Vincent-Salomon, A de Cremoux, P Couturier, J Palangie, T Pouillard, P
Citation: P. Beuzeboc et al., Herceptin, a monoclonal humanized antibody anti-HER2: a major therapeutic progress in breast cancers overexpressing this oncogene, B CANCER, 86(6), 1999, pp. 544-548
Risultati: 1-18 |